Non-Small Cell Lung Cancer is the most common type of Lung Cancer, making up nearly 80% of all cases. This type of Lung Cancer grows and spreads more slowly than small cell lung cancer. Non-small cell lung cancer is divided into three different subcategories. Squamous cell carcinoma originates in the thin, flat cells that line the passages of the respiratory tract. Adenocarcinoma begins in the cells that form the lining of the lungs. Large cell carcinomas make up a group of cancers that look large and abnormal under a microscope.
About vandetanib (ZACTIMA)
Vandetanib is being studied as a multitargeted compound, directed to the inhibition of key cell signaling pathways involved in tumor growth and spread. Tumor cells are targeted through inhibition of epidermal growth factor receptor (EGFR) and REarranged during Transfection (RET) tyrosine kinases, while tumor blood supply is targeted through inhibition of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase. RET tyrosine kinase activity is an important growth driver in certain lung tumors.
Other studies currently recruiting within the NSCLC Phase III clinical development program are:
-- ZEAL (ZACTIMA Efficacy (or Evaluation) with Alimta in Lung cancer)
-- ZEN (ZACTIMA efficacy in EGFR Failures in Non-small cell lung cancer)
-- ZEST (ZACTIMA Efficacy when Studied versus Tarceva)
The primary endpoints for these studies are PFS and OS.
ZACTIMA(TM) is a trademark of the AstraZeneca group of companies.
AstraZeneca is a major international healthcare business engaged in the
research, development, manufacture and marketing of prescription
pharmaceuticals and the supply of healthcare services. It is one of the
world's leading pharmaceutical companies with healthcare sales of $26.47
billion and leading positions in sales of gastrointestinal, cardiovascular,
neuroscience, respiratory, oncolo
Copyright©2007 PR Newswire.
All rights reserved